Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day

Kevin Travers16:17 ET

Sanofi Becomes Latest Drugmaker to Challenge HHS Over 340B Drug-discount Program

Seeking Alpha11:50 ET

Market Climbs, Bitcoin Close to $100k | Live Stock

Kevin Travers11:06 ET

Johnson & Johnson Applies for FDA Approval of Tremfya Subcutaneous Induction Regimen for Ulcerative Colitis

MT NewswiresNov 22 08:47 ET

Dividend Roundup: General Mills, Halliburton, Johnson & Johnson, Coca-Cola, and Others

Seeking AlphaNov 22 08:40 ET

Express News | Johnson & Johnson Seeks U.S. FDA Approval for Subcutaneous Induction Regimen of Tremfya® (Guselkumab) in Ulcerative Colitis, a First for an Il-23 Inhibitor

ReutersNov 22 08:00 ET